-
2023-508956-20-00
5
2020-03-12
Hidradenitis suppurativa
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-513734-38-00
5
2019-07-03
Prevention of breast cancer in women with a BRCA1 germline mutation
-
2024-512444-29-00
5
2019-05-07
patients who will undergo kidney, liver or kidney-pancreatic
transplan
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-513637-20-00
4
2017-03-24
Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-520155-24-00
4
2025-10-16
Metastatic castration resistant prostate cancer (mCRPC)
-
2024-519575-26-00
4
2025-07-25
Chronic pulmonary aspergillosis (CPA)
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2024-513266-19-00
5
2025-06-13
Hidradenitis Suppurativa (HS)
-
2024-517818-15-00
9
2025-06-06
Non-Small Cell Lung Cancer
-
2024-516814-39-00
5
2025-05-20
Chronic rhinosinusitis with nasal polyps